Home » ARENA TO BEGIN TRIAL FOR OBESITY DRUG CANDIDATE
ARENA TO BEGIN TRIAL FOR OBESITY DRUG CANDIDATE
Arena Pharmaceuticals has reported that based on the 12- and six-month preclinical toxicology studies of the company's obesity drug candidate, APD356, the company expects to initiate a Phase III program in the second half of 2006.
APD356 is a novel and selective 5-HT2C receptor agonist for obesity. Based on preclinical data, APD356 has been shown to help patients reduce their weight in an effective, safe and controlled manner.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May